Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deffered Revenue: 2017-2018

  • Iovance Biotherapeutics' Non-Current Deffered Revenue fell 22.56% to $230,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $230,000, marking a year-over-year decrease of 22.56%. This contributed to the annual value of $230,000 for FY2018, which is 22.56% down from last year.
  • As of Q4 2018, Iovance Biotherapeutics' Non-Current Deffered Revenue stood at $230,000, which was down 22.56% from $297,000 recorded in Q4 2017.
  • In the past 5 years, Iovance Biotherapeutics' Non-Current Deffered Revenue registered a high of $297,000 during Q4 2017, and its lowest value of $230,000 during Q4 2018.
  • Its 2-year average for Non-Current Deffered Revenue is $263,500, with a median of $263,500 in 2017.
  • Data for Iovance Biotherapeutics' Non-Current Deffered Revenue shows a maximum YoY fell of 22.56% (in 2018) over the last 5 years.
  • Iovance Biotherapeutics' Non-Current Deffered Revenue (Quarterly) stood at $297,000 in 2017, then declined by 22.56% to $230,000 in 2018.